Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

NCT02648711 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision

Conditions

Solid Tumors

Interventions

DRUG: CRLX101
DRUG: Bevacizumab
DRUG: mFOLFOX6

Sponsor

NewLink Genetics Corporation